Educational guide
Targeted LNP Formulation
Targeted LNP Formulation mRNA Delivered Where It Matters Home » IVT RNA Production Services » Targeted Lipid Nanoparticle (LNP) Formulation Services Targeted Lipid Nanoparticle (LNP) Formulation Services At GenScript, we are committed to pushing the boundaries
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Targeted LNP Formulation
mRNA Delivered Where It Matters
Home » IVT RNA Production Services » Targeted Lipid Nanoparticle (LNP) Formulation Services
Targeted Lipid Nanoparticle (LNP) Formulation Services
At GenScript, we are committed to pushing the boundaries of innovation in the field of lipid nanoparticle (LNP) technology. Building on the success and reliability of our current LNP services, we are thrilled to announce the launch of our Targeted LNP Service—designed to revolutionize the precision and efficacy of therapeutic delivery.
This advanced service leverages cutting-edge lipid formulations and targeting ligands to ensure that therapeutic payloads reach their intended destinations with unparalleled accuracy. Whether you're developing gene therapies, mRNA vaccines, or other innovative treatments, our Targeted LNP Service could offer advanced solutions to your mRNA and LNP projects.
Accuracy
Customizable targeting ligands to direct LNPs to specific cells or tissues.
Improved Efficacy
Increased mRNA expression at the target site
Versatility
A Wide Array of Targeting Options to Optimize Payload Delivery
Rush mRNA Synthesis New!
GMP-like mRNA Manufacturing Services
Catalog IVT mRNA, circRNA, saRNA, LNP products
mRNA QC Analysis
GenScript Cap Technology
Circular RNA Synthesis
Self-Amplifying RNA
LNP Formulation
Targeted LNP Formulation
ReadyEdit LNP Formulation
Targeted LNP Service
Target Options
T Cell Targeted LNP: CD3-Ab/LNP
CD34+ cell targeted LNP: CD34-Ab/LNP
Liver targeted LNP: Tri-GalNac/LNP, 20DODAP LNP
Spleen targeted LNP: SM10218PA LNP
Lung Targeted LNP: 50DOTAP LNP, CD31-Ab/LNP
Macrophage targeted LNP: Mannose/LNP
Kidney enhanced delivery: KKEEE/LNP
Corresponding Case Studies Below
QC Testing
Encapsulation Efficiency: >85%
Size Distribution: POI ±20 nm
Polydispersity Index: <0.2
Zeta potential: ± 15 mV
pH: 7.4 ± 0.5
Endotoxin : <4 EU/ml
Size/Scale Options
Load 20 nt ~ 20 kb mRNA
Load 0.1- gram level mRNA
Administration
Intramuscular (I.M.) for animal use only
Intravenous (I.V.) for animal use only
For in vitro studies
Novel LNP formulation
CX108
CX175
SM-CX712
CX108 LNP exhibited comparable in vivo performance to the benchmark SM102 LNP, and demonstrated enhanced expression in primary T cells after CD3 antibody conjugation, highlighting its potential for in vivo CAR-T applications.
CX175 LNP exhibited comparable in vivo performance to the benchmark SM102 LNP, and demonstrated enhanced expression in primary T cells after CD3 antibody conjugation, highlighting its potential for in vivo CAR-T applications.
SM-CX712 LNP can enhance RNA’s distribution to muscle, and reduce its expression in liver by IM injection
Popular off-the-shelf mRNA_LNP catalogs available now!
Ready-to-use targeted LNPs for specific cell and tissue delivery including T cells, CD34+ stem cells, liver (TriGalNAc, 20DODAP), and spleen (18PA) pre-loaded with mRNAs expressing eGFP or F-Luciferase, available in 5 days
“Not sure which T-cell targeted LNP fits your application? Check our LNP selector tool for guidance.”
Quality Control and Specification
Appearance
Visual Inspect
Clear and free of foreign particles
Final Concentration
RiboGreen assay
0.05 – 0.4 mg/mL
Encapsulation Efficiency
> 85%
Encapsulated RNA Integrity
Bioanalyzer
> 75%
Particle size
Dynamic light scattering
Particle sizes differ with different LNP formulations
Poly Dispersity Index
< 0.2
Zeta Potential
Zetasizer by dynamic light scattering
Zeta potential varies with different LNP formulations
pH
pH paper
7.4 ± 0.5
Endotoxin
Quantitative
<4 EU/ml
Bioburden
Direct inoculation
No Growth after 72 hrs
Lipid Composition
LC-CAD
as detected
Upon Request
Antibody conjugation efficiency
Bradford assay
CD3-Ab/LNP
T Cells
Ligand decorated
Up to 4 payloads
65-165 nm
±20mV
CD34-Ab/LNP
CD34+ Cells
Tri-GalNac/LNP
Liver
65-125 nm
±15mV
CD31-Ab/LNP
Lung
Mannose/LNP
Macrophage
KKEEE/LNP
Kidney
20DODAP LNP
Formulation optimized
SM10218PA LNP
Spleen
-30 ~ +10 mV
50DOTAP LNP
-10 ~ +30 mV
Case Studies
Fluc mRNA(N1-methyl-pseU) was encapsulated with SM102-LNP or SM102-LNP decorated with anti-Human CD3 Antibody (Clone: OKT3, mAb, Mouse, GenScript, A02199), 100ng of mRNA encapsulated in LNP were incubated with jurkat cells in RPMI140 +10%FBS at 37C for 24 hrs. The expression of Fluc was detected using Luciferase Assay (Promega, E4030).
eGFP mRNA(N1-methyl-pseU) was encapsulated with SM102-LNP or SM102-LNP decorated with anti-Human CD3 Antibody (Clone OKT3, mAb, Mouse, GenScript), 10-150ng of mRNA encapsulated in LNP were incubated with primary T cells for 24 hrs. The expression of eGFP was detected using flow cytometry. W1, W2 and W3 indicate different wash conditions.
Fluc mRNA(N1-methyl-pseU) was encapsulated with SM102-LNP or SM102-LNP decorated with anti-mouse CD3 Antibody, 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice, after 24 hrs, mice were sacrificed, and the expression of Fluc mRNA was measured with whole body imaging with different organs.
*Not sure which T-cell targeted LNP fits your application? Check our LNP selector tool for guidance >>
Resting primary T cells were seeded at 1 × 10⁶ cells per well in a 24-well plate and transfected with 500 ng of generic LNP, CD3Ab-LNP, or CD5Ab-LNP. The anti-human CD3 antibody (OKT3, mAb, mouse, GenScript) and anti-human CD5 antibody (mAb, Rabbit, GenScript) were used for LNP surface decoration. T-cell expression was assessed by flow cytometry (FACS) at 48 h post-transfection. Because CD3Ab (OKT3) is known to activate primary T cells, CD3Ab-LNP exhibited a higher expression level compared with CD5Ab-LNP. Notably, despite the intrinsic difficulty of transfecting resting T cells, CD5Ab-LNP still achieved over 80% transfection-positive cells.
Resting primary T cells were seeded at 1 × 10⁶ cells per well in a 24-well plate and transfected with 500 ng of generic LNP, CD3Ab-LNP, CD4Ab-LNP, or CD8Ab-LNP. The anti-human CD3 antibody (OKT3, mAb, mouse, GenScript), anti-human CD4 antibody (F001, mAb, mouse, GenScript), and anti-human CD8 antibody (F002, mAb, mouse, GenScript) were used for LNP surface decoration. T-cell expression was assessed by flow cytometry (FACS) at 48 h post-transfection. CD4Ab-LNP and CD8Ab-LNP exhibited selective delivery to CD4⁺ and CD8⁺ T cells, respectively, with minimal off-target expression.
EGFP mRNA(N1-methyl-pseU) was encapsulated with SM102-LNP or SM102-LNP decorated with anti-Human CD34 Antibody (Purified anti-human CD34 antibody(Anti-Human CD34 Antibody, mAb, Mouse, GenScript, CP0001) 100ng of mRNA encapsulated in LNP were incubated with Kasumi-1 cells for 24 hrs. The expression of eGFP was detected using flow cytometry.
EGFP mRNA(N1-methyl-pseU) was encapsulated with ALC0315-LNP or ALC0315-LNP decorated with anti-Human CD34 Antibody (Purified anti-human CD34 antibody(Anti-Human CD34 Antibody, mAb, Mouse, GenScript, CP0001) 100ng of mRNA encapsulated in LNP were incubated with primary human CD34+ cells for 24 hrs. The expression of eGFP was detected using flow cytometry.
Fluc mRNA(N1-methyl-pseU) was encapsulated with LNP , 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice, after 24 hrs, mice were sacrificed, and the expression of Fluc mRNA was measured with whole body imaging with different organs.
EGFP mRNA(N1-methyl-pseU) was encapsulated with SM102-LNP or SM102-LNP decorated with TriGalNac, 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice, after 24 hrs, mice were sacrificed, and liver organs were lysed. The eGFP expression in lysate was detected using western blot method.
Fluc mRNA (m1Ψ) was encapsulated with LNP, 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice. Conjugation of anti-CD31 antibodies to LNPs can enhance mRNA expression levels in the lungs of mice. FACS analysis of lung cells revealed that CD31-Ab/LNPs exhibit clear targeting specificity toward CD31⁺ cells.
Fluc mRNA (m1Ψ) was encapsulated with LNP, 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice. Mannose/LNP improved Fluc mRNA expression in spleen and lymph node system.
Mannose/LNPs delivering sgRNA targeting Zeb2 achieved efficient gene editing in Cas9⁺ BMDM cells and significantly suppressed tumors in a Cas9-GFP mouse model.
Fluc mRNA (m1Ψ) was encapsulated with LNP, 0.3mg/kg of mRNA encapsulated in LNP were injection through tail vein into mice. KKEEE/SM102 LNP enhanced Fluc mRNA expression in kidney organ ~4.6 times comparing undecorated LNP.
FAQs
We accept various antibody formats for targeted LNP conjugation, including:
Full-length antibodies (IgG)
scFv (single-chain variable fragments)
Fab fragments
VHH (nanobodies)
Other antibody formats
If you have questions about a specific antibody format, please contact our technical team to discuss compatibility.
Antibody-Decorated LNP Platforms for Targeted T-Cell Delivery
Antibody-decorated lipid nanoparticles (LNPs) enable non-viral, cell-specific nucleic acid delivery to immune cell subsets. By selecting antibodies against well-characterized T-cell surface markers, LNPs can be tuned for broad immune engagement, precision immunomodulation, or selective cytotoxic enhancement, supporting applications from in vivo CAR-T to autoimmune and infectious disease therapies.
CD3-LNP
Primary Target Cell Population
Best-Fit Disease Applications
Key Cons / Limitations
CD3 engagement may activate T cells (risk of cytokine release)
Limited cell-type specificity
Requires careful antibody density/affinity tuning
CD4-LNP
Does not target cytotoxic CD8+ T cells
Risk of altering helper/Treg balance
Potential off-target immune modulation
CD5-LNP
Expression on both T and B cells reduces specificity
Biological role in signaling is complex
Weaker targeting signal than CD3/CD7
CD7-LNP
Broad expression on normal T/NK cells
Potential on-target toxicity
Less suitable for non-oncology indications
CD8-LNP
Excludes CD4+ helper/Treg populations
Lower total T-cell reach than CD3-LNP
May require combination strategies
REQUEST A QUOTE
PHONE
1-877-436-7274
ONLINE FORM
Online Quote Submission
FAX
1-732-210-0262